163 related articles for article (PubMed ID: 34358524)
1. MCL1 inhibition enhances the efficacy of docetaxel against airway-derived squamous cell carcinoma cells.
Sakuma Y; Hirai S; Sumi T; Tada M; Kojima T; Niki T; Yamaguchi M
Exp Cell Res; 2021 Sep; 406(2):112763. PubMed ID: 34358524
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition.
Weeden CE; Ah-Cann C; Holik AZ; Pasquet J; Garnier JM; Merino D; Lessene G; Asselin-Labat ML
Oncogene; 2018 Aug; 37(32):4475-4488. PubMed ID: 29743589
[TBL] [Abstract][Full Text] [Related]
3. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells.
Tada M; Sumi T; Tanaka Y; Hirai S; Yamaguchi M; Miyajima M; Niki T; Takahashi H; Watanabe A; Sakuma Y
Lung Cancer; 2019 Jul; 133():88-95. PubMed ID: 31200834
[TBL] [Abstract][Full Text] [Related]
4. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
5. Aurora-A/NF-ĸB Signaling Is Associated With Radio-resistance in Human Lung Adenocarcinoma.
Liu JB; Hu L; Yang Z; Sun YU; Hoffman RM; Yi Z
Anticancer Res; 2019 Nov; 39(11):5991-5998. PubMed ID: 31704824
[TBL] [Abstract][Full Text] [Related]
6. A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically.
Wang XS; Ding XZ; Li XC; He Y; Kong DJ; Zhang L; Hu XC; Yang JQ; Zhao MQ; Gao SG; Lin TY; Li Y
Nanomedicine; 2018 Oct; 14(7):2103-2114. PubMed ID: 30047470
[TBL] [Abstract][Full Text] [Related]
7. Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation.
Qin S; Zhang B; Xiao G; Sun X; Li G; Huang G; Gao X; Li X; Wang H; Yang C; Ren H
Tumour Biol; 2016 Oct; 37(10):13509-13520. PubMed ID: 27465556
[TBL] [Abstract][Full Text] [Related]
8. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X
Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T
Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266
[TBL] [Abstract][Full Text] [Related]
9. [Effect of silencing LASP1 on biological behaviors of oral squamous cell carcinoma cells and IC50 of three anti-tumor drugs].
Chen Q; Wang X; Yu YC; Wei KJ
Shanghai Kou Qiang Yi Xue; 2019 Feb; 28(1):13-19. PubMed ID: 31080993
[TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
11. The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Goodwin J; Neugent ML; Lee SY; Choe JH; Choi H; Jenkins DMR; Ruthenborg RJ; Robinson MW; Jeong JY; Wake M; Abe H; Takeda N; Endo H; Inoue M; Xuan Z; Yoo H; Chen M; Ahn JM; Minna JD; Helke KL; Singh PK; Shackelford DB; Kim JW
Nat Commun; 2017 May; 8():15503. PubMed ID: 28548087
[TBL] [Abstract][Full Text] [Related]
12. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
[TBL] [Abstract][Full Text] [Related]
13. Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.
Bilguun EO; Kaira K; Kawabata-Iwakawa R; Rokudai S; Shimizu K; Yokobori T; Oyama T; Shirabe K; Nishiyama M
BMC Cancer; 2020 Sep; 20(1):935. PubMed ID: 32993587
[TBL] [Abstract][Full Text] [Related]
14. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
15. Interplay between protein acetylation and ubiquitination controls MCL1 protein stability.
Shimizu K; Gi M; Suzuki S; North BJ; Watahiki A; Fukumoto S; Asara JM; Tokunaga F; Wei W; Inuzuka H
Cell Rep; 2021 Nov; 37(6):109988. PubMed ID: 34758305
[TBL] [Abstract][Full Text] [Related]
16. Co-expression of podoplanin and fibroblast growth factor 1 predicts poor prognosis in patients with lung squamous cell carcinoma.
Li J; Chen H; Li X; Wang L; Gao A; Zhang P; Lin W; Gao W; Yang D; Guo X; Liu J; Dang Q; Sun Y
Mol Med Rep; 2017 Aug; 16(2):1643-1652. PubMed ID: 28656229
[TBL] [Abstract][Full Text] [Related]
17. Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity.
Wu D; Pang Y; Wilkerson MD; Wang D; Hammerman PS; Liu JS
Br J Cancer; 2013 Sep; 109(6):1599-608. PubMed ID: 24002593
[TBL] [Abstract][Full Text] [Related]
18. Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma.
Vallejo-Díaz J; Olazabal-Morán M; Cariaga-Martínez AE; Pajares MJ; Flores JM; Pio R; Montuenga LM; Carrera AC
Oncotarget; 2016 Dec; 7(51):85063-85078. PubMed ID: 27835880
[TBL] [Abstract][Full Text] [Related]
19. EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival.
Hirai S; Tada M; Yamaguchi M; Niki T; Sakuma Y
Biochem Biophys Res Commun; 2020 May; 526(2):417-423. PubMed ID: 32223928
[TBL] [Abstract][Full Text] [Related]
20. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.
Kotschy A; Szlavik Z; Murray J; Davidson J; Maragno AL; Le Toumelin-Braizat G; Chanrion M; Kelly GL; Gong JN; Moujalled DM; Bruno A; Csekei M; Paczal A; Szabo ZB; Sipos S; Radics G; Proszenyak A; Balint B; Ondi L; Blasko G; Robertson A; Surgenor A; Dokurno P; Chen I; Matassova N; Smith J; Pedder C; Graham C; Studeny A; Lysiak-Auvity G; Girard AM; Gravé F; Segal D; Riffkin CD; Pomilio G; Galbraith LC; Aubrey BJ; Brennan MS; Herold MJ; Chang C; Guasconi G; Cauquil N; Melchiore F; Guigal-Stephan N; Lockhart B; Colland F; Hickman JA; Roberts AW; Huang DC; Wei AH; Strasser A; Lessene G; Geneste O
Nature; 2016 Oct; 538(7626):477-482. PubMed ID: 27760111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
